4,452 Shares in Insmed, Inc. (NASDAQ:INSM) Purchased by Neo Ivy Capital Management

Key Points

• Neo Ivy Capital Management has acquired a new stake in Insmed, Inc. by purchasing 4,452 shares, valued at approximately $340,000, in its most recent SEC filing.
• Insider trading activity includes CEO William Lewis selling 129,805 shares for over $13 million, reflecting a 35.69% decrease in his position.
• Several analysts have recently upgraded their ratings and target prices for Insmed, leading to a consensus rating of "Moderate Buy" with an average price target of $109.20.

Neo Ivy Capital Management bought a new position in Insmed, Inc. (NASDAQ:INSM - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 4,452 shares of the biopharmaceutical company's stock, valued at approximately $340,000.

Several other hedge funds also recently bought and sold shares of the company. Cullen Frost Bankers Inc. lifted its position in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares during the last quarter. Elequin Capital LP bought a new stake in Insmed during the fourth quarter valued at approximately $28,000. NBC Securities Inc. bought a new stake in Insmed during the first quarter valued at approximately $49,000. Versant Capital Management Inc lifted its position in Insmed by 546.3% during the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 590 shares during the last quarter. Finally, Signaturefd LLC lifted its position in Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after purchasing an additional 325 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on INSM shares. Wells Fargo & Company lifted their target price on shares of Insmed from $119.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, July 22nd. Morgan Stanley boosted their price objective on shares of Insmed from $102.00 to $108.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Leerink Partners boosted their price objective on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. HC Wainwright boosted their price objective on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Finally, UBS Group lowered their price objective on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $109.20.

Insmed Trading Up 1.0%

Insmed stock traded up $1.10 during mid-day trading on Wednesday, reaching $106.10. 741,507 shares of the company traded hands, compared to its average volume of 2,738,120. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. The firm's 50 day moving average price is $91.98 and its 200 day moving average price is $80.33. The firm has a market capitalization of $20.13 billion, a price-to-earnings ratio of -17.80 and a beta of 0.90. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.06) earnings per share. On average, analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Activity at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the sale, the insider directly owned 89,407 shares of the company's stock, valued at $8,352,401.94. This represents a 52.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Martina M.D. Flammer sold 9,925 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $65.47, for a total transaction of $649,789.75. Following the completion of the sale, the insider directly owned 86,596 shares in the company, valued at $5,669,440.12. This represents a 10.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 606,597 shares of company stock valued at $55,120,762 in the last 90 days. 3.00% of the stock is owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.